Evonik has officially opened its newly upgraded active pharmaceutical ingredient (API) manufacturing facility in Lafayette, Indiana, marking an important step in strengthening pharmaceutical production in the U.S. The company is investing US$100 million over the next five years to modernize the site, improve production capabilities, and meet the growing demand for U.S.-based contract manufacturing services. The investment reflects the increasing need for reliable domestic pharmaceutical manufacturing as healthcare companies seek secure supply chains and advanced production facilities. The modernization project is also expected to support local economic development while securing more than 650 jobs at the Lafayette location. With enhanced automation and upgraded equipment, the facility is positioned to deliver higher efficiency, improved reliability, and greater manufacturing flexibility for pharmaceutical customers.
According to Towards Healthcare, the plant-based API market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 41.43 billion in 2026 to approximately USD 81.73 billion by 2035, representing a compound annual growth rate (CAGR) of 7.84% from 2026 to 2035. Rising demand for naturally sourced pharmaceutical ingredients, expanding investment in sustainable drug manufacturing, and continuous advancements in botanical extraction technologies are creating strong opportunities. Increasing regulatory support, consumer preference for plant-derived medicines, and growing research collaborations further accelerate innovation and market expansion globally.
The Tippecanoe Labs site in Lafayette is recognized as one of the world's largest facilities dedicated to the production of active pharmaceutical ingredients. It also houses one of the industry's largest high-potency API manufacturing operations. As part of the modernization project, Evonik is upgrading large-scale reactors and other critical production systems to improve operational performance and workplace ergonomics. These improvements are expected to increase manufacturing efficiency while supporting the production of increasingly complex pharmaceutical compounds. The facility produces pharmaceutical intermediates, active pharmaceutical ingredients, and excipients that are widely used in drug development and manufacturing. By expanding its technical capabilities, Evonik aims to better serve pharmaceutical companies seeking contract development and manufacturing services within the United States. The investment also strengthens the company's ability to support advanced therapies that require sophisticated production technologies.
In a recent quote, Guido Skudlarek, head of the Health Care business line, Evonik, said, "Strengthening our U.S. drug substance business is a strategic necessity. With demand surging, Tippecanoe plays a pivotal role in creating a more resilient and globally balanced asset footprint."
Also, Daniel Fricker, head of the Drug Substance product line, Evonik Health Care, said, "API complexity continues to rise, and this investment empowers us to work with our customers on even more challenging molecules for critical indications, such as cancer and metabolic and cardiovascular diseases.
Evonik's expansion is part of a broader trend of major industrial investments taking place across Indiana. Several manufacturers have announced new projects aimed at increasing production capacity, creating jobs, and strengthening the state's manufacturing ecosystem. Construction equipment manufacturer Caterpillar recently announced additional investments in workforce training, while Merrell Bros is expanding its headquarters and factory operations through a multi-million-dollar project.
South Korean company Hanjung America Corp. has also selected Indiana for its first U.S. manufacturing facility focused on battery system components. These investments demonstrate Indiana's growing importance as a destination for advanced manufacturing and industrial development. For the pharmaceutical industry, Evonik's new API manufacturing facility represents another significant milestone in improving domestic production capacity, supporting supply chain resilience, and meeting the increasing demand for high-quality pharmaceutical ingredients. The project is expected to contribute to future innovation, reliable medicine production, and long-term growth across the U.S. healthcare industry.
Evonik's investment in advanced API manufacturing infrastructure supports the broader plant-based API market by expanding high-quality production capabilities and improving manufacturing efficiency. Modernized facilities, enhanced automation, and expertise in handling complex pharmaceutical ingredients can accelerate the development and commercialization of plant-derived active ingredients. Increased U.S.-based contract manufacturing capacity also encourages pharmaceutical companies to invest in botanical drug research, strengthens supply chain resilience, and creates new opportunities for innovation, sustainable production, and wider adoption of plant-based pharmaceutical solutions worldwide.
A recent report by Towards Healthcare highlights that the plant-based API market is witnessing robust growth due to increasing demand for herbal therapeutics, cleaner manufacturing practices, and expanding pharmaceutical research. Growing awareness of environmentally friendly production methods, rising investments in biotechnology, and the development of advanced extraction techniques are strengthening market potential. Collaborations between pharmaceutical companies and botanical researchers, supportive regulatory initiatives, and increasing adoption of plant-derived ingredients in chronic disease treatments are expected to create long-term growth opportunities worldwide.
